
The notion that the cerebellum is a central regulator of motor function is undisputed. There exists, however, considerable literature to document a similarly vital role for the cerebellum in the regulation of various non-motor domains, including emotion. Research from numerous avenues of investigation (i.e., neurophysiological, behavioural, electrophysiological, imagining, lesion, and clinical studies) have documented the importance of the cerebellum, in particular, the vermis, in affective processing that appears preserved across species. The cerebellum possesses a distinct laminar arrangement and highly organized neuronal circuitry. Moreover, the cerebellum forms reciprocal connections with several brain regions implicated in diverse functional domains, including motor, sensory, and emotional processing. It has been argued that these unique neuroanatomical features afford the cerebellum with the capacity to integrate information about an organism, its environment, and its place within the environment such that it can respond in an appropriate, coordinated fashion, with such theories extending to the regulation of emotion. This review puts our current understanding of the cerebellum and its role in behaviour in historical perspective, presents an overview of the neuroanatomical and functional organization of the cerebellum, and reviews the literature describing the involvement of the cerebellum in emotional regulation in both humans and non-human animals. In summary, this review discusses the importance of the functional connectivity of the cerebellum with various brain regions in the ability of the cerebellum to effectively regulate emotional behaviour.
Citation: Wanda M. Snow, Brenda M. Stoesz, Judy E. Anderson. The Cerebellum in Emotional Processing: Evidence from Human and Non-Human Animals[J]. AIMS Neuroscience, 2014, 1(1): 96-119. doi: 10.3934/Neuroscience.2014.1.96
[1] | Huafei Di, Yadong Shang, Jiali Yu . Existence and uniform decay estimates for the fourth order wave equation with nonlinear boundary damping and interior source. Electronic Research Archive, 2020, 28(1): 221-261. doi: 10.3934/era.2020015 |
[2] | Yi Cheng, Ying Chu . A class of fourth-order hyperbolic equations with strongly damped and nonlinear logarithmic terms. Electronic Research Archive, 2021, 29(6): 3867-3887. doi: 10.3934/era.2021066 |
[3] | Ibtissam Issa, Zayd Hajjej . Stabilization for a degenerate wave equation with drift and potential term with boundary fractional derivative control. Electronic Research Archive, 2024, 32(8): 4926-4953. doi: 10.3934/era.2024227 |
[4] | Xu Liu, Jun Zhou . Initial-boundary value problem for a fourth-order plate equation with Hardy-Hénon potential and polynomial nonlinearity. Electronic Research Archive, 2020, 28(2): 599-625. doi: 10.3934/era.2020032 |
[5] | Shuting Chang, Yaojun Ye . Upper and lower bounds for the blow-up time of a fourth-order parabolic equation with exponential nonlinearity. Electronic Research Archive, 2024, 32(11): 6225-6234. doi: 10.3934/era.2024289 |
[6] | Gongwei Liu . The existence, general decay and blow-up for a plate equation with nonlinear damping and a logarithmic source term. Electronic Research Archive, 2020, 28(1): 263-289. doi: 10.3934/era.2020016 |
[7] | Xiaoqiang Dai, Chao Yang, Shaobin Huang, Tao Yu, Yuanran Zhu . Finite time blow-up for a wave equation with dynamic boundary condition at critical and high energy levels in control systems. Electronic Research Archive, 2020, 28(1): 91-102. doi: 10.3934/era.2020006 |
[8] | Yang Liu, Wenke Li . A family of potential wells for a wave equation. Electronic Research Archive, 2020, 28(2): 807-820. doi: 10.3934/era.2020041 |
[9] | Hami Gündoğdu . RETRACTED ARTICLE: Impact of damping coefficients on nonlinear wave dynamics in shallow water with dual damping mechanisms. Electronic Research Archive, 2025, 33(4): 2567-2576. doi: 10.3934/era.2025114 |
[10] | Liangliang Li . Chaotic oscillations of 1D wave equation with or without energy-injections. Electronic Research Archive, 2022, 30(7): 2600-2617. doi: 10.3934/era.2022133 |
The notion that the cerebellum is a central regulator of motor function is undisputed. There exists, however, considerable literature to document a similarly vital role for the cerebellum in the regulation of various non-motor domains, including emotion. Research from numerous avenues of investigation (i.e., neurophysiological, behavioural, electrophysiological, imagining, lesion, and clinical studies) have documented the importance of the cerebellum, in particular, the vermis, in affective processing that appears preserved across species. The cerebellum possesses a distinct laminar arrangement and highly organized neuronal circuitry. Moreover, the cerebellum forms reciprocal connections with several brain regions implicated in diverse functional domains, including motor, sensory, and emotional processing. It has been argued that these unique neuroanatomical features afford the cerebellum with the capacity to integrate information about an organism, its environment, and its place within the environment such that it can respond in an appropriate, coordinated fashion, with such theories extending to the regulation of emotion. This review puts our current understanding of the cerebellum and its role in behaviour in historical perspective, presents an overview of the neuroanatomical and functional organization of the cerebellum, and reviews the literature describing the involvement of the cerebellum in emotional regulation in both humans and non-human animals. In summary, this review discusses the importance of the functional connectivity of the cerebellum with various brain regions in the ability of the cerebellum to effectively regulate emotional behaviour.
It has been almost two years since the outbreak of COVID-19. A large number of international research results have given us a certain understanding of the virus. This is a severe respiratory illness caused by the coronavirus [1,2]. The International Committee on Taxonomy of viruses named the virus SARS-CoV-2 is mainly transmitted through respiratory tract. The clinical symptoms of infected people are mostly fever, dry cough and fatigue, and some patients are asymptomatic infected people. When the disease is serious, it will also cause organ failure and even death [3,4].
Currently, the COVID-19 pandemic is still ongoing. According to the latest outbreak of the World Health Organization, as of October 2021, there were more than 70 million newly confirmed cases in Europe [5]. The United Kingdom is one of the worst-affected countries in Europe, with more than 8 million cumulative cases, of which more than 7 million were diagnosed in England alone [6], accounting for 85% of the total cumulative cases reported in the United Kingdom.
Since more than 80% of confirmed cases in Britain are concentrated in England, we intend to do some theoretical research based on the data of England for the reference of government decision-making. Figure 1 shows the daily new cases data of COVID-19 epidemic in England during 2020 [6]. In early March, due to the obvious increase of new cases, the British government began to implement the first large-scale social blockade at the end of March and gradually unsealed at the beginning of June. This phase corresponds to the phase in which the first small peak appears in Figure 1. In the three months after the first unsealing, the epidemic situation in the region had been relatively gentle. However, since September, the number of new cases per day had increased significantly. By the end of October, the number of new cases per day had reached about 20000.At this time, the British government once again announced that it would implement the second large-scale social blockade on November 5, which lasted until December 2nd. Soon after the second unsealing, the third wave of more large-scale epidemic began, and there were reports that a mutant virus with stronger transmission ability was detected, and the epidemic reached a stage that was difficult to control. On December 20th, Britain ushered in the third social blockade, which lasted until February 2021.
H. Ward et al. based on antibody levels in 365,000 people, showed that at the start of the second wave of infections in England, only 4.4% of adults had IgG antibodies detected using text for lateral flow immunoassay (LFIA) [7]. A study on the antibody positive rate of asymptomatic and symptomatic infected people in Wanzhou District of Chongqing by Quanxin Long et al showed that after 8 weeks of infection, the antibody concentration of more than 90% of the participants decreased by more than 70% [8]. A study on the neutralizing antibody level of SARS-CoV-2 patients within three months after infection found that after analyzing the serum samples of 65 SARS-CoV-2 infected patients, 95% of the cases had seroconversion [9]. Some researchers found that the antibody titers of the two virus strains decreased significantly, and the delta variant virus strain decreased more significantly than the wild strain [10,11,12]. The infectious disease dynamics model is a key tool for studying the spread of infectious diseases. It is generally divided into four compartments, susceptible (S), exposed (E), infected (I) and recovered (R) compartments. It can clearly describe the dynamic relationship between various warehouses in the process of virus transmission, and give relatively accurate predictions on the development trend of infectious diseases. P. Wintachai [13] et al. predicted the change trend of COVID-19 cases over time by establishing SEIR infectious disease dynamics model considering different vaccination rates. A. Fuady [14] et al. established an infectious disease dynamics model considering different vaccination times to explore the inhibitory effect of changes in vaccination time on the spread of covid-19 epidemics. M. Angeli et. al. [15] et al introduced SAIVR mathematical model to forecast the covid-19 epidemic evolution during the vaccination campaign by employing a semi-supervised machine learning process. S. Zhai [16] et al. studied an SEIR-type epidemic model with time delay and vaccination control, the vaccination strategy was expressed as a state delayed feedback which was related to the current and previous state of the epidemic model and investigated the non-negativity and boundedness of the model. J. Medina [17] et al. modeled a trustable and reliable management system based on block chain for vaccine distribution by extending the SEIR model, which included prevention measures such as mask-wearing, social distancing, vaccination rate, and vaccination efficiency. A. Karabay [18] et al. presented a particle-based SEIR epidemic simulator as a tool to assess the impact of different vaccination strategies on viral propagation and to model sterilizing and effective immunization outcomes and the simulator included modules to support contact tracing of the interactions amongst individuals and epidemiological testing of the general population. J. Wieland [19] et al. developed a model for the simulation of the SARS Cov-2 spread in Germany in the context of a complementary course at the Leuphana University. It tried to simulate different scenarios of the number of cases with the help of ODE. Chen [20] et al. used compartmental models to model and analyze the COVID-19 dynamics of different considered populations as susceptible, exposed, infected and rcovered compartments (SEIR). They derived control-oriented compartmental models of the pandemic, together with constructive control laws based on the Lyapunov theory. Antibody levels decrease over time after a person recovers from COVID-19, there will be a chance of re-infection with the virus. In the first model, we explore the impact of declining antibody levels on the spread of the COVID-19 epidemic in the UK, taking into account that a certain proportion of recoveries would become susceptible again. In the optimized model, we add the vaccinated compartment and study the impact of the vaccine's effect on the outbreak.
This study selects the daily new data of the COVID-19 epidemic in England from September 1 to October 31, 2020 as the data for model fitting, that is, the data in the middle and early stages of the second wave of the epidemic in England. Based on these possible factors: 1) The first wave of the epidemic has ended, and the level of antibodies in the infected people began to decline; 2) The British government did not have any intervention policy during this period; 3) There was no vaccination during this period; Therefore we used data for this time period when considering the impact of declining antibody levels on the spread of COVID-19 in this model.
Because the spread of COVID-19 has a long incubation period and the incubation period is contagious, in our model, we consider the incubation period and adopt the SEIR model. We divide the total population N into four categories: susceptible (S), exposed (E), infected (I), and recovered (R). $ \beta $ is the rate of disease transmission, $ \sigma $ is the conversion rate from exposed people to infected people, $ \gamma $ is the disease recovery rate, $ \mu $ is the mortality due to disease, and $ P $ is the conversion rate from recovered group to susceptible group. The SEIR infectious disease dynamics model considering the decline of antibody level is shown in Figure 2.
According to the above COVID-19 spread diagram, we establish the infectious disease dynamics model as follows:
$ {dS/dt=−βS(E+I)+PR,dE/dt=βS(E+I)−σE,dI/dt=σE−(μ+γ)I,dR/dt=γI−PR. $
|
(2.1) |
We obtain, when $ I = 0 $, the disease-free equilibrium point of model (2.1) is $ E_{01} = (S_0, 0, 0, 0) $.When $ I\neq0 $, the endemic equilibrium point of model (2.1) is
$ {E_1}^* = \left( {\frac{{{S_0}}}{{{R_0}}},\frac{{\gamma + \mu }}{\sigma }{I^*},{I^*},\frac{\gamma }{P}{I^*}} \right),{I^*} \ne 0. $ |
The basic reproduction number refers to the average number of secondary cases after an infected individual enters the susceptible population [21], the next generation matrix is the most commonly used method to calculate the basic reproduction number.
In order to calculate the basic reproduction number of model (2.1), we take
$ \mathscr{F} = \left( βS(E+I)0 \right), \mathscr{V} = \left( σE−σE+(γ+μ)I \right). $
|
The Jacobian matrices of F and V are
$ F = \left( {βSβS00 } \right), V = \left( {σ0−σγ+μ } \right). $
|
At disease-free equilibrium, we obtain
$ {\left. {FV^{-1}} \right|_{{E_{01}}}} = \left( {βS0σ+βS0γ+μβS0γ+μ00 } \right). $
|
The basic reproduction number $ \mathscr{R}_0 $ is the spectral radius of $ {\left. {F{V^{ - 1}}} \right|_{{E_{01}}}} $, so the expression is
$ {\mathscr{R}_0} = \frac{{\beta {S_0}\left( {\sigma+\gamma+\mu} \right)}}{{\sigma \left( {\gamma + \mu } \right)}}. $ |
Theorem 1. When $ \mathscr{R}_0 < 0 $, model (2.1) is stable at the disease-free equilibrium point, otherwise unstable.
Proof. The Jacobian matrix of model (2.1) at $ E_{01} $ is
$ {\left. J \right|_{{E_{01}}}} = \left( {0−βS0−βS000βS0−σβS000σ−(γ+μ)000γ−P } \right). $
|
The matrix eigenvalue satisfies the following formula:
$ |λE−J|E01|=|λβS0βS000λ−βS0+σ−βS000−σλ+γ+μ000−γλ+P|=λ(λ+P)[λ2+(σ+γ+μ−βS0)λ+σ(γ+μ)−βS0(σ+γ+μ)]. $
|
Obviously $ {\lambda _1} = 0, {\lambda _2} = - P < 0 $, the other two eigenvalues $ {\lambda _3}, \; {\lambda _4} $ satisfy the equation
$ P\left( \lambda \right) = {\lambda ^2} + {a_1}\lambda + {a_2} = 0, $ |
where
$ {a_1} = \sigma + \gamma + \mu - \beta {S_0},\;{a_2} = \sigma \left( {\gamma + \mu } \right) - \beta {S_0}\left( {\sigma + \gamma + \mu } \right). $ |
Easy to know
$ \frac{{\beta {S_0}}}{{\sigma + \gamma + \mu }} = {\mathscr{R}_0}\frac{{\sigma \left( {\gamma + \mu } \right)}}{{{{\left( {\sigma + \gamma + \mu } \right)}^2}}} < 1, $ |
therefore,
$ a1=σ+γ+μ−βS0>0,a2=σ(γ+μ)−βS0(σ+γ+μ)=σ(γ+μ)(1−R0). $
|
So, when $ \mathscr{R}_0 < 1 $, we obrain $ {a_1} > 0 $ and $ {a_2} > 0 $. According to Hurwitz discriminant method, the characteristic roots $ {\lambda _3}, \; {\lambda _4} $ of $ P(\lambda) $ have negative real parts.
To sum up, among the eigenvalues of the Jacobian matrix of model (2.1), the real part of four eigenvalues is negative and one is zero. So, when $ \mathscr{R}_0 < 1 $, model (2.1) is stable at the disease-free equilibrium point, otherwise unstable.
Antibody levels decline over time, and herd immunity approaches that rely on natural immunity become unfeasible. Therefore, on the basis of the above model (2.1), we add the vaccination compartment (people who were successfully vaccinated) to establish the SEIRV model. In this model, we consider daily vaccination of susceptible populations at a fixed vaccination rate and explore the impact of varying injection and failure rates on the outbreak in England. The propagation mechanism of the model is shown in the Figure 3. Here $ \alpha $ refers to the daily proportion of vaccination, $ \omega $ is the vaccine failure rate and refers to the reciprocal of the duration of vaccine effectiveness. The other parameters are the same of model (2.1).
According to the above COVID-19 diagram, the infectious disease dynamics model we established is
$ {dS/dt=−αS−(1−α)βS(E+I)+PR+ωV,dE/dt=(1−α)βS(E+I)−σE,dI/dt=σE−(γ+μ)I,dR/dt=γI−PR,dV/dt=αS−ωV. $
|
(3.1) |
Let
$ \left\{ −αS−(1−α)βS(E+I)+PR+ωV=0,(1−α)βS(E+I)−σE=0,σE−(γ+μ)I=0,γI−PR=0,αS−ωV=0. \right. $
|
When $ I = 0 $, there are
$ S = {S_0},E = 0,R = 0,V = \frac{{\alpha {S_0}}}{\omega }. $ |
The disease-free equilibrium point of model (3.1) is
$ {E_{02}} = ({S_0},0,0,0,\frac{{\alpha {S_0}}}{\omega }). $ |
When $ I\neq0 $, we obtain
$ {S^*} = \frac{{{S_0}}}{{{\mathscr{R}_0}}},{E^*} = \frac{{\gamma + \mu }}{\sigma }{I^*},{R^*} = \frac{\gamma }{P}{I^*},{V^*} = \frac{{\alpha {S_0}}}{{\omega {\mathscr{R}_C}}}. $ |
Therefore, the endemic equilibrium point of model (3.1) is
$ {E_2}^* = \left( {\frac{{{S_0}}}{{{\mathscr{R}_C}}},\frac{{\gamma + \mu }}{\sigma }{I^*},{I^*},\frac{\gamma }{P}{I^*},\frac{{\alpha {S_0}}}{{\omega {\mathscr{R}_C}}}} \right),{I^*} \ne 0. $ |
The number of controlled reproduction refers to the number of people who can be infected by an infected person during the infection period under certain prevention and control measures [22]. It is also calculated by the method of next generation matrix.
In order to calculate the control reproduction number of model (3.1), we take
$ \mathscr{F} = \left( (1−α)βS(E+I)0 \right), \mathscr{V} = \left( σE−σE+(γ+μ)I \right). $
|
The Jacobian matrices of F and V are
$ F = \left( {(1−α)βS(1−α)βS00 } \right),V = \left( {σ0−σγ+μ } \right). $
|
At disease-free equilibrium, there is
$ {\left. {F{V^{ - 1}}} \right|_{{E_{02}}}} = \left( {(1−α)βS0σ+(1−α)βS0γ+μ(1−α)βS0γ+μ00 } \right). $
|
The control reproduction number is the spectral radius of $ {\left. {F{V^{ - 1}}} \right|_{{E_{02}}}} $, and the expression is
$ {\mathscr{R}_C} = \frac{{\left( {1 - \alpha } \right)\beta {S_0}\left( {\sigma + \gamma + \mu } \right)}}{{\sigma \left( {\gamma + \mu } \right)}}. $ |
Theorem 2. When $ {\mathscr{R}_C} < 1 $, the model (3.1) is locally asymptotically stable at the disease-free equilibrium point, otherwise it is unstable.
Proof. The Jacobian matrix of model (3.1) at $ {E_{02}} $ is
$ {\left. J \right|_{{E_{02}}}} = \left( {−α−(1−α)βS0−(1−α)βS0Pω0(1−α)βS0−σ(1−α)βS0000σ−(γ+μ)0000γ−P0α000−ω } \right). $
|
The matrix eigenvalue satisfies the following formula:
$ \begin{array}{*{20}{l}} {\left| {\lambda E - J\left| {_{{E_{02}}}} \right.} \right|}& = &{\left| {\begin{array}{*{20}{c}} {\lambda + \alpha }&{\left( {1 - \alpha } \right)\beta {S_0}}&{\left( {1 - \alpha } \right)\beta {S_0}}&{ - P}&{ - \omega }\\ 0&{\lambda - \left( {1 - \alpha } \right)\beta {S_0} + \sigma }&{ - \left( {1 - \alpha } \right)\beta {S_0}}&0&0\\ 0&{ - \sigma }&{\lambda + \gamma + \mu }&0&0\\ 0&0&{ - \gamma }&{\lambda + P}&0\\ { - \alpha }&0&0&0&{\lambda + \omega } \end{array}} \right|}\\ {}& = &\begin{array}{l} \left( {\lambda + P} \right)\left[ {{\lambda ^2} + \left( {\alpha + \omega } \right)\lambda + 2\alpha \omega } \right]\\ \left\{ {{\lambda ^2} + \left[ {\sigma + \gamma + \mu - \left( {1 - \alpha } \right)\beta {S_0}} \right]\lambda + \sigma \left( {\gamma + \mu } \right) - \left( {1 - \alpha } \right)\beta {S_0}\left( {\sigma + \gamma + \mu } \right)} \right\}. \end{array} \end{array} $
|
Obviously $ {\lambda _1} = - P < 0 $, the other eigenvalues $ {\lambda _2}, \; {\lambda _3} $ satisfy the equation
$ {P_1}\left( \lambda \right) = {\lambda ^2} + {A_1}\lambda + {A_2}, $ |
where
$ {A_1} = \omega + \alpha ,{A_2} = 2\omega \alpha . $ |
We obtain
$ {\Delta _1} = 1 > 0,{\Delta _2} = \left| {A110A2 } \right| = \left| {ω+α102ωα } \right| > 0, $
|
which means $ {\lambda _2} $ and $ {\lambda _3} $ have negative real parts. The last two eigenvalues $ {\lambda _4}, \; {\lambda _5} $ satisfy the equation
$ {P_2}\left( \lambda \right) = {\lambda ^2} + {B_1}\lambda + {B_2}, $ |
where
$ {B_1} = \sigma + \gamma + \mu - \left( {1 - \alpha } \right)\beta {S_0},{B_2} = \sigma \left( {\gamma + \mu } \right) - \left( {1 - \alpha } \right)\beta {S_0}\left( {\sigma + \gamma + \mu } \right). $ |
So, when $ \mathscr{R}_C < 1 $, we obrain $ {B_1} > 0 $ and $ {B_2} > 0 $. According to Hurwitz discriminant method, the characteristic roots $ {\lambda _4} $ and $ {\lambda _5} $ have negative real parts.
To sum up, all eigenvalues of the Jacobian matrix of model (3.1) have negative real parts, so model (3.1) is locally asymptotically stable at the disease-free equilibrium point, otherwise it is unstable.
According to model (2.1), the number of new cases per day in England from September 1 to October 31 is fitted by the nonlinear least squares method, and the fitting result is shown in Figure 4. Within the allowable range of error, we set the initial value of the susceptible as $ {S_0} = 55699400 $, the initial value of exposed people as $ {E_0} = 6500 $, the initial value of infected people as $ {I_0} = 1041 $, meaning the number of new cases in England on September 1, and the initial value of recovered people as 200. The conversion rate from exposed people to infected people is $ \sigma = 1/12\; (day^{-1}) $ [23], the recovery rate of disease is $ \gamma = 1/14 \; (day^{-1}) $ [24] and the mortality rate is $ \mu = 0.003 $ [25], which are selected according to the actual transmission of infectious diseases. And we obtain the transmission rate is $ \beta = 1.1295 \times {10^{ - 9}} $ and the conversion rate from the recovered group to susceptible group is $ P = 1.8888 \times 10{}^{ - 6} $ by fitting.
The fitting results of the improved SEIR model are in good agreement with the England data, and can better reflect the growth trend of the COVID-19 epidemic in England.
In the SEIRV model (3.1), $ \alpha $ refers to the daily vaccination rate, which is further explained here. The overall immunization rates corresponding to different daily vaccination rates (60 days after vaccination) is shown in Figure 5. The total population of England is about 50 million, $ \alpha = 0.005 $ means that 250,000 people are vaccinated on the first day. After 60 days of continuous vaccination, the overall immunization rate is 25.9%.
In SEIRV model, the meaning of vaccine failure rate $ \omega $ refers to the reciprocal of the duration of vaccine effectiveness, that is, each corresponds to a duration of vaccine effectiveness. The data details are shown in Table 1.
Vaccine failure rates | Vaccine effective time period (days) |
0 | FOREVER |
0.001 | 1000 |
0.002 | 500 |
0.003 | 333 |
0.004 | 250 |
0.005 | 200 |
0.006 | 167 |
0.007 | 143 |
0.008 | 125 |
0.009 | 111 |
0.01 | 100 |
0.02 | 50 |
0.03 | 33 |
0.04 | 25 |
0.05 | 20 |
In order to evaluate the role of vaccines in epidemic control, we investigate the impact of different vaccination rates and failure rates on the spread of COVID-19 epidemic in England. We change the vaccine failure rate when the fixed vaccination rate is 0.005, and simulate the impact of different failure rates on the spread of COVID-19 epidemic in England. The results are shown in Figures 6–8. In Figure 6, the failure rates are taken from 0 to 0.01 in steps of 0.001; in Figure 7, the failure rate is taken from 0.01 to 0.05 in steps of 0.01; in Figure 8, the failure rate is taken from 0.01 to 0.02 in steps of 0.001. As can be seen from Figures 6–8, with the decrease of vaccine failure rate, the peak of epidemic situation will gradually decrease. When the failure rate is less than 0.01, the peak time will advance with the decrease of failure rate; when the failure rate is greater than 0.01, the peak time will be delayed with the decrease of failure rate. If only Figures 6 and 7 are used to illustrate that 0.01 is the boundary value of peak time trend change, it may be coincidental because the failure rate less than 0.01 is taken as the step of 0.001, and the failure rate greater than 0.01 is taken as the step of 0.01. Therefore, we further take the failure rate from 0.01 to 0.02 in steps of 0.001 for simulation, as shown in Figure 8. It can be seen from Figure 8 that the time of peak value is delayed with the decrease of failure efficiency. In general, when the step of failure rate change is 0.001, the simulation shows that when the fixed vaccination rate is 0.005, the peak of epidemic situation will decrease with the decrease of failure efficiency. When the failure rate is less than 0.01, the peak time will advance with the decrease of failure efficiency; when the failure rate is greater than 0.01, the peak time will be delayed with the decrease of failure efficiency. When the vaccination rate is 0.005, the line chart of the epidemic peak under different vaccine failure rates is shown in Figure 9. When the value of failure rate is large (greater than 0.02), the peak will increase significantly. When the failure rate is 0.001 the peak value is 81.4% lower than the peak value when the failure rate is 0.01, and when the failure rate is 0.01 the peak value is 89.5% lower than the peak value when the failure rate is 0.02. Therefore, the lower the vaccine failure rate, the lower the peak of the epidemic. The peak values under different failure rates are shown in Table 2.
Vaccine failure rates | Vaccine effective time period (days) | Peak value | Peak time (days) |
0 | FOREVER | 17126 | 101 |
0.001 | 1000 | 17934 | 106 |
0.002 | 500 | 18887 | 113 |
0.003 | 333 | 20032 | 121 |
0.004 | 250 | 21443 | 130 |
0.005 | 200 | 23244 | 143 |
0.006 | 167 | 25658 | 160 |
0.007 | 143 | 29159 | 187 |
0.008 | 125 | 35046 | 239 |
0.009 | 111 | 49967 | 435 |
0.01 | 100 | 96669 | 634 |
0.02 | 50 | 924,980 | 445 |
0.03 | 33 | 1,481,000 | 383 |
0.04 | 25 | 1,823,700 | 355 |
0.05 | 20 | 2,050,800 | 339 |
When the vaccination rate is 0.005, the line chart of the peak time of epidemic situation under different vaccine failure rates is shown in Figure 10. It can be seen when the failure rate is less than 0.01, the peak time will advance with the decrease of failure rate; when the failure rate is greater than 0.01, the peak time will be delayed with the decrease of failure rate. When the failure rate is 0.01, the peak time is 528 days later than that when the failure rate is 0.001 and 295 days later than that when the failure rate is 0.05. The peak time under different failure rates is shown in Table 2.
We also discuss the number of new cases per day at 30, 40, 50, 60 and 70 days in England with different failure rates when the vaccination rate is 0.005. The results are shown in Figure 11. It can be seen from the figure that at the same time, the smaller the failure rate, the fewer the number of cases. On the 60th day of vaccination, the vaccine with failure rate of 0.002 is 5.8% lower than the vaccine with failure rate of 0.01; on the 70th day of vaccination, the vaccine with failure rate of 0.002 is 9.1% lower than the vaccine with failure rate of 0.01. Therefore, with the extension of time, the vaccine with low failure rate is more effective in reducing the number of cases than the vaccine with high failure rate. The number of cases is shown in Table 3.
30 days | 40 days | 50 days | 60 days | 70 days | |
$ \omega=0.002 $ | 8337 | 10214 | 12079 | 13862 | 15476 |
$ \omega=0.006 $ | 8366 | 10305 | 12298 | 14307 | 16276 |
$ \omega=0.010 $ | 8393 | 10390 | 12502 | 14720 | 17020 |
When the vaccination rate is 0.01, we discuss the impact of different vaccine failure rates on the spread of the epidemic in England, the results are shown in Figures 12–15. The simulation results show that the smaller the failure rate is, the lower the peak of epidemic situation is, and 0.019 is the boundary value of failure rate. When the failure rate is less than 0.019, the peak time will advance with the decrease of failure rate; when the failure rate is greater than 0.019, the peak time will be delayed with the decrease of failure rate. Some data are shown in Table 4.
failure rates | 0 | 0.005 | 0.01 | 0.015 | 0.019 | 0.02 | 0.021 |
Peak value | 8856 | 9452 | 10354 | 12125 | 38455 | 66507 | 101150 |
Peak time (days) | 54 | 62 | 75 | 110 | 979 | 956 | 892 |
When the vaccine failure rate is 0.005, the impact of different vaccination rates on the spread of the epidemic in England is shown in Figure 16. The vaccination rates change from 0.005 to 0.025 in steps of 0.005. According to the simulation, the peak of epidemic situation decreases with the increase of vaccination rate, and the peak time advances with the increase of vaccination rate. When the vaccination rate is 0.025, the peak value decrease by 74.8% and the peak time is 114 days earlier than that when the vaccination rate is 0.005. The result is given in Table 5.
Vaccination rate | 0.005 | 0.01 | 0.015 | 0.02 | 0.025 |
Peak value | 23244 | 9452 | 7269 | 6370 | 5857 |
Peak time (days) | 143 | 62 | 42 | 34 | 29 |
In order to comprehensively evaluate the effects of vaccination rate and failure rate on the peak infection cases and peak time, we add heat-maps for peak infection cases and peak times, the results are shown in Figures 17 and 18. The vaccination rates change from 0.002 to 0.005 in steps of 0.001 and the vaccine failure rates change from 0.001 to 0.01 in steps of 0.001.
The first part of this study is to develop an improved SEIR model of COVID-19 transmission in England taking into account the decline in antibody levels in recovers. In the second part, a SEIRV vaccination model is established on the basis of the decline in antibody levels, taking into account that susceptible populations are vaccinated at a fixed vaccination rate every day. We calculate the basic reproduction number of model (2.1) and the control reproduction number of model (3.1), calculate the disease-free equilibrium point and endemic equilibrium point of the two models, and analyze the stability of the model.
In the numerical simulation part, we further explain the vaccination rate and failure rate: $ \alpha = 0.005 $ means that 250,000 people are vaccinated every day on the basis of 50 million people in England, on the basis of this vaccination rate, the overall immunization rate is 25.9% after 60 days of continuous vaccination. In addition, the meaning of vaccine failure rate $ \omega $ refers to the reciprocal of the duration of vaccine effectiveness, that is, each corresponds to a duration of vaccine effectiveness.
In model (3.1), we investigate the impact of different failure rates on the spread of the epidemic in England when the vaccination rates are 0.005 and 0.01. The results shows that when the fixed vaccination rate is 0.005, when the failure rate is 0.001, the peak value is 81.4% lower than that when the failure rate is 0.01, and when the failure rate is 0.01the peak value is 89.5% lower than that when the failure rate is 0.02. In addition, when the failure rate is 0.01, the peak time is 528 days later than when the failure rate is 0.001 and 295 days later than when the failure rate is 0.05. Therefore, the peak of epidemic situation will decrease with the decrease of failure efficiency. The peak time of the epidemic has two situations. When the failure rate is less than 0.01, the peak time will advance with the decrease of failure efficiency; when the failure rate is greater than 0.01, the peak time will be delayed with the decrease of failure efficiency. On the 60th day of vaccination, the vaccine with failure rate of 0.002 is 5.8% lower than the vaccine with failure rate of 0.01, on the 70th day of vaccination, the vaccine with failure rate of 0.002 is 9.1% lower than the vaccine with failure rate of 0.01. Therefore, with the extension of time, the vaccine with low failure rate is more effective in reducing the number of cases than the vaccine with high failure rate. When the fixed vaccination rate is 0.01, the peak of epidemic situation will decrease with the decrease of failure efficiency. When the failure rate is less than 0.019, the peak time will advance with the decrease of failure efficiency; when the failure rate is greater than 0.019, the peak time will be delayed with the decrease of failure efficiency. We also investigate the impact of different vaccination rates on the spread of the epidemic in England when the fixed vaccine failure rate is 0.005. The peak of epidemic situation decreases with the increase of vaccination rate, and the peak time is advanced with the increase of vaccination rate. When the vaccination rate is 0.025, the peak value decreases by 74.8% and the peak time is 114 days earlier than that when the vaccination rate was 0.005.
The rationality of the fitting value of $ P = 1.8888 \times 10{}^{ - 6} $. This fitting value refers to the level of antibody decline in the actual recovered patients, including not only the number of hospitalizations officially counted, but also the number of uncounted patients with moderate and mild symptoms, and the number of confirmed asymptomatic infections. This value is somewhat underestimated. If only the number of recovered patients in hospital is counted according to official data from the UK government, this fitted value may have practical significance. Antibody levels take longer to drop due to higher antibody levels in severely recovered patients [26].
In model (3.1), the meaning of the vaccine failure rate refers to the inverse of the effective duration of the vaccine, that is, the failure rate corresponds to the effective duration of an effective vaccine. The data details are shown in Table 1. Similarly, the vaccination rate corresponds to a time period in which vaccinations are completed, for example $ \alpha = 0.005 $ indicating that it takes 200 days to complete all vaccinations.
In the numerical simulation part, the peak always decreases as the vaccine failure rate decreases. Peak arrival times may be related to boundary values. When the failure rate is less than the boundary value, the peak time will advance as the failure rate decreases; when the failure rate is greater than the boundary value, the peak time will be delayed as the failure rate decreases. In this study, when the vaccination rate was 0.005, the boundary value for the failure rate was 0.01; when the vaccination rate was assumed to be 0.01, the boundary value for the failure rate was 0.019. The boundary values in this paper are based on the failure rate with a step size of 0.001, when we take a smaller step size for simulation, we may get more accurate failure rate boundary values.
Israel has one of the highest vaccination rates in the world [27]. On December 20, 2020, the country took the lead in launching the world's first universal vaccination program for COVID-19. According to the official website of the Israeli Ministry of Health [28], as of March 2, 2020, the proportion of Israel receiving one dose of the vaccine was 51.67%, and the proportion of receiving two doses of the new crown vaccine was 37.53%. By early August 2021, about 62% of Israel's 9.3 million population had received at least one dose of the vaccine, and about 58% had completed two doses. Israel, despite reaching such a high vaccination rate, saw a new peak of cases in early September 2021. According to the World Health Organization, on September 1, 2021, Israel recorded more than 10,000 new cases per day. By the end of August 2021, the vaccination rate in Singapore had reached 80%, and since September 2021, the number of new cases in Singapore has increased significantly, and by the end of October, there were more than 5,000 new cases in a single day.
This article explores the impact of different vaccine failure rates on the spread of the COVID-19 outbreak in the UK, given a certain vaccination rates. Although many countries have achieved high vaccination rates, and even theoretically achieved rates of herd immunity, from the data alone, vaccination does not seem to have a significant inhibitory effect on the epidemic in these countries. The reason may be that the mutated virus is difficult to deal with, or the vaccine is not as effective as expected. In the next article, we will use data from severe cases to assess vaccine efficacy and protection. Vaccination rates can be increased through government policies, but if the protection rate of the vaccine itself is not high, increasing the vaccination rate will not help to fundamentally control the epidemic.
This study was funded by Natural Science Foundation of China (NSFC 11901027, 11871093), the China Postdoctoral Science Foundation(2021M703426), Postgraduate Teaching Research and Quality Improvement Project of BUCEA (J2021010), BUCEA Post Graduate Innovation Project (2021098, 2021099). We thank all the individuals who generously shared their time and materials for this study.
The authors declare there is no conflict of interest.
[1] | Andersen BB, Korbo L, Pakkenberg B. (1992) A quantitative study of the human cerebellum with unbiased stereological techniques. J Comp Neurol 326(4): 549-60. |
[2] | Glickstein M, Doron K. (2008) Cerebellum: Connections and functions. Cerebellum 7(4):589-94. |
[3] | Gibb R, Kolb B. (1999) A method for vibratome sectioning of golgi-cox stained whole rat brain. J Neurosci Methods 79(1): 1-4. |
[4] |
Ito M. (2002) Historical review of the significance of the cerebellum and the role of purkinje cells in motor learning. Ann N Y Acad Sci 978: 273-88. doi: 10.1111/j.1749-6632.2002.tb07574.x
![]() |
[5] | Eccles JC, Ito M, Szentágothai J. (1967) The Cerebellum as a Neuronal Machine. New York: NY Springer-Verlag. |
[6] | Marr D. (1960) A theory of cerebellar cortex. J Physiol 202(2): 437-70. |
[7] |
Albus JS. (1971) A theory of cerebellar function. Math Biosci 10: 25-61. doi: 10.1016/0025-5564(71)90051-4
![]() |
[8] |
Thach WT, Goodkin HP, Keating JG. (1992) The cerebellum and the adaptive coordination of movement. Ann Rev Neurosci 15: 403-42. doi: 10.1146/annurev.ne.15.030192.002155
![]() |
[9] | Leiner HC, Leiner AL, Dow RS. (1986) Does the cerebellum contribute to mental skills? Behav Neurosci 100(4): 443-54. |
[10] | Keele SW, Ivry R. (1990) Does the cerebellum provide a common computation for diverse tasks? A timing hypothesis. Ann NY Acad Sci 608: 207-11. |
[11] |
Petersen SE, Fox PT, Posner MI, et al. (1989) Positron emission tomographic studies of the processing of single words. J Cognitive Neurosci 1: 153-170. doi: 10.1162/jocn.1989.1.2.153
![]() |
[12] |
Strick PL, Dum RP, Fiez JA. (2009) Cerebellum and nonmotor function. Annu Rev Neurosci 32:413-34. doi: 10.1146/annurev.neuro.31.060407.125606
![]() |
[13] |
DOW RS. (1961) Some aspects of cerebellar physiology. J Neurosurg 18: 512-30. doi: 10.3171/jns.1961.18.4.0512
![]() |
[14] | Kandel ER, Schwartz JH, Jessell TM. (2000) Principles of neural science. 4Eds, New York: McGraw-Hill, Health Professions Division, 1414 . |
[15] |
Berntson GG, Torello MW. (1982) The paleocerebellum and the integration of behavioural function. Physiol Psychol 10: 2-12. doi: 10.3758/BF03327003
![]() |
[16] |
Middleton FA, Strick PL. (1997) Cerebellar output channels. Int Rev Neurobiol 41: 61-82. doi: 10.1016/S0074-7742(08)60347-5
![]() |
[17] | Hashimoto M, Hibi M. (2012) Development and evolution of cerebellar neural circuits. Dev Growth Differ 54(3): 373-89. |
[18] | Ito M. (2006) Cerebellar circuitry as a neuronal machine. Prog Neurobiol 78(3-5): 272-303. |
[19] | Eccles JC. (1967) Circuits in the cerebellar control of movement. Proc Natl Acad Sci USA58(1): 336-43. |
[20] | Akshoomoff NA, Courchesne E. (1992) A new role for the cerebellum in cognitive operations. Behav Neurosci 106(5): 731-8. |
[21] | Decety J, Sjoholm H, Ryding E, Stenberg G, Ingvar DH. (1990) The cerebellum participates in mental activity: Tomographic measurements of regional cerebral blood flow. Brain Res 535(2):313-7. |
[22] | Ryding E, Decety J, Sjoholm H, et al. (1993) Motor imagery activates the cerebellum regionally. A SPECT rCBF study with 99mTc-HMPAO. Brain Res Cogn Brain Res 1(2): 94-9. |
[23] | Kim SG, Ugurbil K, Strick PL. (1994) Activation of a cerebellar output nucleus during cognitive processing. Science 265(5174): 949-51. |
[24] |
Schmahmann JD, Sherman JC. (1998) The cerebellar cognitive affective syndrome. Brain 121:561-79. doi: 10.1093/brain/121.4.561
![]() |
[25] | Exner C, Weniger G, Irle E. (2004) Cerebellar lesions in the PICA but not SCA territory impair cognition. Neurology 63(11): 2132-5. |
[26] | Marien P, de Smet HJ, Wijgerde E, et al. (2013) Posterior fossa syndrome in adults: A new case and comprehensive survey of the literature. Cortex 49(1): 284-300. |
[27] | Kuper M, Timmann D. (2013) Cerebellar mutism. Brain Lang 127(3): 327-33. |
[28] | Baillieux H, De Smet HJ, Paquier PF, et al. (2008) Cerebellar neurocognition: Insights into the bottom of the brain. Clin Neurol Neurosurg 110(8): 763-73. |
[29] | Steinlin M, Imfeld S, Zulauf P, et al. (2003) Neuropsychological long-term sequelae after posterior fossa tumour resection during childhood. Brain 126(Pt 9): 1998-2008. |
[30] |
Levisohn L, Cronin-Golomb A, Schmahmann JD. (2000) Neuropsychological consequences of cerebellar tumour resection in children: Cerebellar cognitive affective syndrome in a paediatric population. Brain 123: 1041-50. doi: 10.1093/brain/123.5.1041
![]() |
[31] | de Smet HJ, Baillieux H, Wackenier P, et al. (2009) Long-term cognitive deficits following posterior fossa tumor resection: A neuropsychological and functional neuroimaging follow-up study. Neuropsychology 23(6): 694-704. |
[32] | Pollack IF, Polinko P, Albright AL, et al. (1995) Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: Incidence and pathophysiology. Neurosurgery37(5): 885-93. |
[33] | Ozimek A, Richter S, Hein-Kropp C, et al. (2004) Cerebellar mutism––report of four cases. J Neurol 251(8): 963-72. |
[34] | Daniels SR, Moores LE, DiFazio MP. (2005) Visual disturbance associated with postoperative cerebellar mutism. Pediatr Neurol 32(2): 127-30. |
[35] | Riva D. (1998) The cerebellar contribution to language and sequential functions: Evidence from a child with cerebellitis. Cortex 34(2): 279-87. |
[36] | Drost G, Verrips A, Thijssen HO, et al. (2000) Cerebellar involvement as a rare complication of pneumococcal meningitis. Neuropediatrics 31(2): 97-9. |
[37] | Fujisawa H, Yonaha H, Okumoto K, et al. (2005) Mutism after evacuation of acute subdural hematoma of the posterior fossa. Childs Nerv Syst 21(3): 234-6. |
[38] | Ersahin Y, Mutluer S, Saydam S, Barcin E. (1997) Cerebellar mutism: Report of two unusual cases and review of the literature. Clin Neurol Neurosurg 99(2): 130-4. |
[39] | Al-Anazi A, Hassounah M, Sheikh B, et al. (2001) Cerebellar mutism caused by arteriovenous malformation of the vermis. Br J Neurosurg 15(1): 47-50. |
[40] | Dubey A, Sung WS, Shaya M, et al. (2009) Complications of posterior cranial fossa surgery––an institutional experience of 500 patients. Surg Neurol 72(4): 369-75. |
[41] | Afshar-Oromieh A, Linhart H, Podlesek D, et al. (2010) Postoperative cerebellar mutism in adult patients with lhermitte-duclos disease. Neurosurg Rev 33(4): 401-8. |
[42] | Coplin WM, Kim DK, Kliot M, et al. (1997) Mutism in an adult following hypertensive cerebellar hemorrhage: Nosological discussion and illustrative case. Brain Lang 59(3): 473-93. |
[43] | Moore MT. (1969) Progressive akinetic mutism in cerebellar hemangioblastoma with "normal-pressure hydrocephalus". Neurology 19(1): 32-6. |
[44] | Caner H, Altinors N, Benli S, et al. (1999) Akinetic mutism after fourth ventricle choroid plexus papilloma: Treatment with a dopamine agonist. Surg Neurol 51(2): 181-4. |
[45] | Idiaquez J, Fadic R, Mathias CJ. (2001) Transient orthostatic hypertension after partial cerebellar resection. Clin Auton Res 21(1): 57-9. |
[46] | De Smet HJ, Marien P. (2012) Posterior fossa syndrome in an adult patient following surgical evacuation of an intracerebellar haematoma. Cerebellum 11(2): 587-92. |
[47] | Dunwoody GW, Alsagoff ZS, Yuan SY. (1997) Cerebellar mutism with subsequent dysarthria in an adult: Case report. Br J Neurosurg 11(2): 161-3. |
[48] | Marien P, Verslegers L, Moens M, et al. (2013) Posterior fossa syndrome after cerebellar stroke. Cerebellum 12(5): 686-91. |
[49] | Sacchetti B, Scelfo B, Strata P. (2005) The cerebellum: Synaptic changes and fear conditioning. Neuroscientist 11(3): 217-27. |
[50] | LeDoux JE. (1994) Emotion, memory and the brain. Sci Am 270(6): 50-7. |
[51] | Maschke M, Schugens M, Kindsvater K, et al. (2002) Fear conditioned changes of heart rate in patients with medial cerebellar lesions. J Neurol Neurosurg Psychiatry 72(1): 116-8. |
[52] | Maschke M, Drepper J, Kindsvater K, et al. (2000) Fear conditioned potentiation of the acoustic blink reflex in patients with cerebellar lesions. J Neurol Neurosurg Psychiatry 68(3):358-64. |
[53] | Turner BM, Paradiso S, Marvel CL, et al. (2007) The cerebellum and emotional experience. Neuropsychologia 45(6): 1331-41. |
[54] | Nashold BS, Wilson WP, Slaughter DG. (1969) Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30(1): 14-24. |
[55] | Damasio AR, Grabowski TJ, Bechara A, et al. (2000) Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 3(10): 1049-56. |
[56] | Ploghaus A, Tracey I, Clare S, et al. (2000) Learning about pain: The neural substrate of the prediction error for aversive events. Proc Natl Acad Sci USA 97(16): 9281-6. |
[57] | Ploghaus A, Tracey I, Gati JS, et al. (1999) Dissociating pain from its anticipation in the human brain. Science 284(5422): 1979-81. |
[58] | Singer T, Seymour B, O'Doherty J, et al. (2004) Empathy for pain involves the affective but not sensory components of pain. Science 303(5661): 1157-62. |
[59] | Fischer H, Andersson JL, Furmark T, et al. (2000) Fear conditioning and brain activity: A positron emission tomography study in humans. Behav Neurosci 114(4): 671-80. |
[60] | Frings M, Maschke M, Erichsen M, et al. (2002) Involvement of the human cerebellum in fear-conditioned potentiation of the acoustic startle response: A PET study. Neuroreport 13(10):1275-8. |
[61] | Timmann D, Drepper J, Frings M, et al. (2010) The human cerebellum contributes to motor, emotional and cognitive associative learning. A review. Cortex 46(7): 845-57. |
[62] | Baumann O, Mattingley JB. (2012) Functional topography of primary emotion processing in the human cerebellum. Neuroimage 61(4): 805-11. |
[63] |
Schienle A, Scharmuller W. (2013) Cerebellar activity and connectivity during the experience of disgust and happiness. Neuroscience 246: 375-81. doi: 10.1016/j.neuroscience.2013.04.048
![]() |
[64] | Schienle A, Stark R, Walter B, et al. (2002) The insula is not specifically involved in disgust processing: An fMRI study. Neuroreport 13(16): 2023-6. |
[65] | Stoodley CJ, Schmahmann JD. (2009) Functional topography in the human cerebellum: A meta-analysis of neuroimaging studies. Neuroimage 44(2): 489-501. |
[66] | Heilman KM, Gilmore RL. (1998) Cortical influences in emotion. J Clin Neurophysiol 15(5):409-23. |
[67] | Fusar-Poli P, Placentino A, Carletti F, et al. (2009) Functional atlas of emotional faces processing: A voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 34(6): 418-32. |
[68] | Vuilleumier P, Pourtois G. (2007) Distributed and interactive brain mechanisms during emotion face perception: Evidence from functional neuroimaging. Neuropsychologia 45(1): 174-94. |
[69] | Schutter DJ, Enter D, Hoppenbrouwers SS. (2009) High-frequency repetitive transcranial magnetic stimulation to the cerebellum and implicit processing of happy facial expressions. J Psychiatry Neurosci 34(1): 60-5. |
[70] | Ferrucci R, Giannicola G, Rosa M, et al. (2012) Cerebellum and processing of negative facial emotions: Cerebellar transcranial DC stimulation specifically enhances the emotional recognition of facial anger and sadness. Cogn Emot 26(5):786-99. |
[71] | Adamaszek M, D'Agata F, Kirkby KC, et al. (2014) Impairment of emotional facial expression and prosody discrimination due to ischemic cerebellar lesions. Cerebellum 13(3):338-45. |
[72] | Furl N, van Rijsbergen NJ, Kiebel SJ, et al. (2010) Modulation of perception and brain activity by predictable trajectories of facial expressions. Cereb Cortex 20(3): 694-703. |
[73] | Kilts CD, Egan G, Gideon DA, et al. (2003) Dissociable neural pathways are involved in the recognition of emotion in static and dynamic facial expressions. Neuroimage 18(1): 156-68. |
[74] | Villanueva R. (2012) The cerebellum and neuropsychiatric disorders. Psychiatry Res 198(3):527-32. |
[75] | Loeber RT, Cintron CM, Yurgelun-Todd DA. (2001) Morphometry of individual cerebellar lobules in schizophrenia. Am J Psychiatry 158(6): 952-4. |
[76] | Okugawa G, Sedvall GC, Agartz I. (2003) Smaller cerebellar vermis but not hemisphere volumes in patients with chronic schizophrenia. Am J Psychiatry 160(9): 1614-7. |
[77] | Jacobsen LK, Giedd JN, Berquin PC, et al. (1997) Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Am J Psychiatry 154(12): 1663-9. |
[78] | Nasrallah HA, Schwarzkopf SB, Olson SC, et al. (1991) Perinatal brain injury and cerebellar vermal lobules I-X in schizophrenia. Biol Psychiatry 29(6): 567-74. |
[79] | Ichimiya T, Okubo Y, Suhara T, et al. (2001) Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia. Biol Psychiatry 49(1): 20-7. |
[80] | Staal WG, Hulshoff Pol HE, Schnack HG, et al. (2000) Structural brain abnormalities in patients with schizophrenia and their healthy siblings. Am J Psychiatry 157(3): 416-21. |
[81] | Aylward EH, Reiss A, Barta PE, et al. (1994) Magnetic resonance imaging measurement of posterior fossa structures in schizophrenia. Am J Psychiatry 151(10): 1448-52. |
[82] | Heath RG. (1977) Modulation of emotion with a brain pacemaker. Treatment for intractable psychiatric illness. J Nerv Ment Dis 165(5): 300-17. |
[83] | Demirtas-Tatlidede A, Freitas C, Cromer JR, et al. (2010) Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia. Schizophr Res 124(1-3):91-100. |
[84] | Manu P, Sarpal D, Muir O, et al. (2011) When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134(2-3): 180-6. |
[85] | Soares JC, Mann JJ. (1997) The anatomy of mood disorders––review of structural neuroimaging studies. Biol Psychiatry 41(1): 86-106. |
[86] | Fitzgerald PB, Laird AR, Maller J, et al. (2008) A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 29(6): 683-95. |
[87] | Leroi I, O'Hearn E, Marsh L, Lyketsos CG, et al. (2002) Psychopathology in patients with degenerative cerebellar diseases: A comparison to huntington's disease. Am J Psychiatry 159(8):1306-14. |
[88] | Alalade E, Denny K, Potter G. (2011) Altered cerebellar-cerebral functional connectivity in geriatric depression. PLoS One 6(5): e20035. |
[89] | Kanner L. (1943) Autistic disturbances of affective contact. Nervous Child 2: 217-50. |
[90] | Senju A, Johnson MH. (2009) Atypical eye contact in autism: Models, mechanisms and development. Neurosci Biobehav Rev 33(8): 1204-14. |
[91] | Ospina MB, Krebs Seida J, Clark B, et al. (2008) Behavioural and developmental interventions for autism spectrum disorder: A clinical systematic review. PLoS One 3(11): e3755. |
[92] | Hughes JR. (2009) Update on autism: A review of 1300 reports published in 2008. Epilepsy Behav 16(4): 569-89. |
[93] | Muratori F, Maestro S. (2007) Autism as a downstream effect of primary difficulties in intersubjectivity interacting with abnormal development of brain connectivity. Inter J Dialog Science 2007(2): 93-118. |
[94] | Bailey A, Luthert P, Dean A, et al. (1998) A clinicopathological study of autism. Brain 121 ( Pt 5)(Pt 5): 889-905. |
[95] | Bauman M, Kemper TL. (1985) Histoanatomic observations of the brain in early infantile autism. Neurology 35(6): 866-74. |
[96] | Courchesne E, Yeung-Courchesne R, Press GA, et al. (1988) Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 318(21): 1349-54. |
[97] | Courchesne E, Hesselink JR, Jernigan TL, et al. (1987) Abnormal neuroanatomy in a nonretarded person with autism. unusual findings with magnetic resonance imaging. Arch Neurol 44(3):335-41. |
[98] | Hashimoto T, Tayama M, Murakawa K, et al. (1995) Development of the brainstem and cerebellum in autistic patients. J Autism Dev Disord 25(1):1-18. |
[99] | Ingram JL, Peckham SM, Tisdale B, et al. (2000) Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 22(3): 319-24. |
[100] | Pierce K, Courchesne E. (2001) Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. Biol Psychiatry 49(8): 655-64. |
[101] | Sparks BF, Friedman SD, Shaw DW, et al. (2002) Brain structural abnormalities in young children with autism spectrum disorder. Neurology 59(2): 184-92. |
[102] | Allen G, Courchesne E. (2003) Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: An fMRI study of autism. Am J Psychiatry160(2): 262-73. |
[103] | Waterhouse L, Fein D, Modahl C. (1996) Neurofunctional mechanisms in autism. Psychol Rev103(3): 457-89. |
[104] | Snow WM, Hartle K, Ivanco TL. (2008) Altered morphology of motor cortex neurons in the VPA rat model of autism. Dev Psychobiol 50(7): 633-9. |
[105] | Allen G, Buxton RB, Wong EC, et al. (1997) Attentional activation of the cerebellum independent of motor involvement. Science 275(5308): 1940-3. |
[106] | Lalonde R, Strazielle C. (2003) The effects of cerebellar damage on maze learning in animals. Cerebellum 2(4): 300-9. |
[107] | Joyal CC, Strazielle C, Lalonde R. (2001) Effects of dentate nucleus lesions on spatial and postural sensorimotor learning in rats. Behav Brain Res 122(2): 131-7. |
[108] | Joyal CC, Meyer C, Jacquart G, et al. (1996) Effects of midline and lateral cerebellar lesions on motor coordination and spatial orientation. Brain Res 739(1-2): 1-11. |
[109] | Leggio MG, Molinari M, Neri P, et al. (2000) Representation of actions in rats: The role of cerebellum in learning spatial performances by observation. Proc Natl Acad Sci USA 97(5):2320-5. |
[110] | Dow RS, Moruzzi G. (1958) The physiology and pathology of the cerebellum. Minneapolis: University of Minnesota Press. |
[111] | Sprague JM, Chambers WW. (1959) An analysis of cerebellar function in the cat, as revealed by its complete and partial destruction, and its interaction with the cerebral cortex. Archs ital Biol 97:68-88. |
[112] |
Chambers WW, Sprague JM. (1955) Functional localization in the cerebellum II. Arch Neurol Psychiat (Chic) 74: 653-680. doi: 10.1001/archneurpsyc.1955.02330180071008
![]() |
[113] | Peters M, Monjan AA. (1971) Behavior after cerebellar lesions in cats and monkeys. Physiol Behav 6(2): 205-6. |
[114] | Berman AS, Berman D, Prescott JW. (1974) The effect of cerebellar lesions on emotional behavior in the rhesus monkey. In: Cooper IS, Riklan M, Snider RS, editors. Ihe Cerebellum, Epilepsy, and Behavior. New York: Plenum, 1974. |
[115] | Supple WF, Leaton RN, Fanselow MS. (1987) Effects of cerebellar vermal lesions on species-specific fear responses, neophobia, and taste-aversion learning in rats. Physiol Behav39(5): 579-86. |
[116] | Barnett SA, Barnett SA. (1975) The rat: a study in behavior. Chicago: University of Chicago. Press. |
[117] | Supple WF, Leaton RN. (1990) Cerebellar vermis: Essential for classically conditioned bradycardia in the rat. Brain Res 509(1): 17-23. |
[118] | Supple WF, Kapp BS. (1993) The anterior cerebellar vermis: Essential involvement in classically conditioned bradycardia in the rabbit. J Neurosci 13(9): 3705-11. |
[119] | Yuzaki M. (2003) The delta2 glutamate receptor: 10 years later. Neurosci Res 46(1): 11-22. |
[120] | Sacchetti B, Scelfo B, Tempia F, et al. (2004) Long-term synaptic changes induced in the cerebellar cortex by fear conditioning. Neuron 42(6): 973-82. |
[121] | Saab CY, Willis WD. (2003) The cerebellum: Organization, functions and its role in nociception. Brain Res Brain Res Rev 42(1): 85-95. |
[122] | Sacchetti B, Baldi E, Lorenzini CA, et al. (2002) Cerebellar role in fear-conditioning consolidation. Proc Natl Acad Sci USA 99(12): 8406-11. |
[123] | Sacchetti B, Scelfo B, Strata P. (2009) Cerebellum and emotional behavior. Neuroscience 162(3):756-62. |
[124] | Butler AB, Hodos H. (1996) Comparative vertebrate neuroanatomy. New York: Wiley-Liss. |
[125] | Rodriguez F, Duran E, Gomez A, et al. (2005) Cognitive and emotional functions of the teleost fish cerebellum. Brain Res Bull 66(4-6): 365-70. |
[126] |
Yoshida M, Kondo H. (2012) Fear conditioning-related changes in cerebellar purkinje cell activities in goldfish. Behav Brain Funct 8: 52. doi: 10.1186/1744-9081-8-52
![]() |
[127] | Supple WF, Sebastiani L, Kapp BS. (1993) Purkinje cell responses in the anterior cerebellar vermis during pavlovian fear conditioning in the rabbit. Neuroreport 4(7): 975-8. |
[128] | Middleton FA, Strick PL. (1994) Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science 266(5184): 458-61. |
[129] | Middleton FA, Strick PL. (2000) Cerebellar projections to the prefrontal cortex of the primate. J Neurosci 21(2):700-12. |
[130] | Middleton FA, Strick PL. (1998) Cerebellar output: Motor and cognitive channels. Trends Cogn Sci 2(9): 348-54. |
[131] | Dietrichs E. (1984) Cerebellar autonomic function: Direct hypothalamocerebellar pathway. Science 223(4636): 591-3. |
[132] | Haines DE, Dietrichs E. (1984) An HRP study of hypothalamo-cerebellar and cerebello-hypothalamic connections in squirrel monkey (saimiri sciureus). J Comp Neurol 229(4):559-75. |
[133] | Snider RS, Maiti A. (1976) Cerebellar contributions to the papez circuit. J Neurosci Res 2(2):133-46. |
[134] | Heath RG. (1972) Physiologic basis of emotional expression: Evoked potential and mirror focus studies in rhesus monkeys. Biol Psychiatry 5(1):15-31. |
[135] | Heath RG, Harper JW. (1974) Ascending projections of the cerebellar fastigial nucleus to the hippocampus, amygdala, and other temporal lobe sites: Evoked potential and histological studies in monkeys and cats. Exp Neurol 45(2): 268-87. |
[136] | Prescott JW. (1971) Early somatosensory deprivation as ontogenic process in the abnormal development of the brain and behavior. In: Moor-Jankowski E, editor. Basel: Karger. |
[137] | D'Angelo E, Casali S. (2013) Seeking a unified framework for cerebellar function and dysfunction: From circuit operations to cognition. Front Neural Circuits 6: 116. |
[138] | Larouche M, Hawkes R. (2006) From clusters to stripes: The developmental origins of adult cerebellar compartmentation. Cerebellum 5(2): 77-88. |
[139] |
Snow WM, Anderson JE, Fry M. (2014) Regional and genotypic differences in intrinsic electrophysiological properties of cerebellar purkinje neurons from wild-type and dystrophin-deficient mdx mice. Neurobiol Learn Mem 107: 19-31. doi: 10.1016/j.nlm.2013.10.017
![]() |
[140] | Stoodley CJ, Schmahmann JD. (2010) Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. Cortex 46(7): 831-44. |
[141] | Schmahmann JD, Caplan D. (2006) Cognition, emotion and the cerebellum. Brain 129(Pt 2):290-2. |
[142] | Leiner HC, Leiner AL, Dow RS. (1989) Reappraising the cerebellum: What does the hindbrain contribute to the forebrain? Behav Neurosci 103(5): 998-1008. |
[143] | Schmahmann JD. (2010) The role of the cerebellum in cognition and emotion: Personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy. Neuropsychol Rev 20(3): 236-60. |
[144] | Nudo RJ, Plautz EJ, Frost SB. (2001) Role of adaptive plasticity in recovery of function after damage to motor cortex. Muscle Nerve 24(8): 1000-19. |
1. | Zefang Song, Huafei Di, Instability analysis and regularization approximation to the forward/backward problems for fractional damped wave equations with random noise, 2023, 01689274, 10.1016/j.apnum.2022.12.017 | |
2. | Yue Pang, Xingchang Wang, Furong Wu, Global existence and blowup in infinite time for a fourth order wave equation with damping and logarithmic strain terms, 2021, 14, 1937-1632, 4439, 10.3934/dcdss.2021115 | |
3. | Quang-Minh Tran, Hong-Danh Pham, Global existence and blow-up results for a nonlinear model for a dynamic suspension bridge, 2021, 14, 1937-1632, 4521, 10.3934/dcdss.2021135 | |
4. | Huafei Di, Zefang Song, F. Rabiei, Initial and Boundary Value Problems for a Class of Nonlinear Metaparabolic Equations, 2021, 2021, 1687-9139, 1, 10.1155/2021/6668355 | |
5. | Nouri Boumaza, Billel Gheraibia, Global existence, nonexistence, and decay of solutions for a wave equation of p-Laplacian type with weak and p-Laplacian damping, nonlinear boundary delay and source terms, 2022, 129, 18758576, 577, 10.3233/ASY-211742 | |
6. | Chao Yang, Yanbing Yang, Long-time behavior for fourth-order wave equations with strain term and nonlinear weak damping term, 2021, 14, 1937-1632, 4643, 10.3934/dcdss.2021110 | |
7. | Yi Cheng, Ying Chu, A class of fourth-order hyperbolic equations with strongly damped and nonlinear logarithmic terms, 2021, 29, 2688-1594, 3867, 10.3934/era.2021066 | |
8. | Le Thi Mai Thanh, Le Thi Phuong Ngoc, Nguyen Huu Nhan, Nguyen Thanh Long, FINITE-TIME BLOW UP OF SOLUTIONS FOR A FOURTH-ORDER VISCOELASTIC WAVE EQUATION WITH DAMPING TERMS, 2023, 13, 2156-907X, 3558, 10.11948/20230162 | |
9. | Wen-jun Liu, Zhi-yu Tu, Equivalence between the internal observability and exponential decay for the Moore-Gibson-Thompson equation, 2024, 39, 1005-1031, 89, 10.1007/s11766-024-4133-5 |
Vaccine failure rates | Vaccine effective time period (days) |
0 | FOREVER |
0.001 | 1000 |
0.002 | 500 |
0.003 | 333 |
0.004 | 250 |
0.005 | 200 |
0.006 | 167 |
0.007 | 143 |
0.008 | 125 |
0.009 | 111 |
0.01 | 100 |
0.02 | 50 |
0.03 | 33 |
0.04 | 25 |
0.05 | 20 |
Vaccine failure rates | Vaccine effective time period (days) | Peak value | Peak time (days) |
0 | FOREVER | 17126 | 101 |
0.001 | 1000 | 17934 | 106 |
0.002 | 500 | 18887 | 113 |
0.003 | 333 | 20032 | 121 |
0.004 | 250 | 21443 | 130 |
0.005 | 200 | 23244 | 143 |
0.006 | 167 | 25658 | 160 |
0.007 | 143 | 29159 | 187 |
0.008 | 125 | 35046 | 239 |
0.009 | 111 | 49967 | 435 |
0.01 | 100 | 96669 | 634 |
0.02 | 50 | 924,980 | 445 |
0.03 | 33 | 1,481,000 | 383 |
0.04 | 25 | 1,823,700 | 355 |
0.05 | 20 | 2,050,800 | 339 |
30 days | 40 days | 50 days | 60 days | 70 days | |
$ \omega=0.002 $ | 8337 | 10214 | 12079 | 13862 | 15476 |
$ \omega=0.006 $ | 8366 | 10305 | 12298 | 14307 | 16276 |
$ \omega=0.010 $ | 8393 | 10390 | 12502 | 14720 | 17020 |
failure rates | 0 | 0.005 | 0.01 | 0.015 | 0.019 | 0.02 | 0.021 |
Peak value | 8856 | 9452 | 10354 | 12125 | 38455 | 66507 | 101150 |
Peak time (days) | 54 | 62 | 75 | 110 | 979 | 956 | 892 |
Vaccination rate | 0.005 | 0.01 | 0.015 | 0.02 | 0.025 |
Peak value | 23244 | 9452 | 7269 | 6370 | 5857 |
Peak time (days) | 143 | 62 | 42 | 34 | 29 |
Vaccine failure rates | Vaccine effective time period (days) |
0 | FOREVER |
0.001 | 1000 |
0.002 | 500 |
0.003 | 333 |
0.004 | 250 |
0.005 | 200 |
0.006 | 167 |
0.007 | 143 |
0.008 | 125 |
0.009 | 111 |
0.01 | 100 |
0.02 | 50 |
0.03 | 33 |
0.04 | 25 |
0.05 | 20 |
Vaccine failure rates | Vaccine effective time period (days) | Peak value | Peak time (days) |
0 | FOREVER | 17126 | 101 |
0.001 | 1000 | 17934 | 106 |
0.002 | 500 | 18887 | 113 |
0.003 | 333 | 20032 | 121 |
0.004 | 250 | 21443 | 130 |
0.005 | 200 | 23244 | 143 |
0.006 | 167 | 25658 | 160 |
0.007 | 143 | 29159 | 187 |
0.008 | 125 | 35046 | 239 |
0.009 | 111 | 49967 | 435 |
0.01 | 100 | 96669 | 634 |
0.02 | 50 | 924,980 | 445 |
0.03 | 33 | 1,481,000 | 383 |
0.04 | 25 | 1,823,700 | 355 |
0.05 | 20 | 2,050,800 | 339 |
30 days | 40 days | 50 days | 60 days | 70 days | |
$ \omega=0.002 $ | 8337 | 10214 | 12079 | 13862 | 15476 |
$ \omega=0.006 $ | 8366 | 10305 | 12298 | 14307 | 16276 |
$ \omega=0.010 $ | 8393 | 10390 | 12502 | 14720 | 17020 |
failure rates | 0 | 0.005 | 0.01 | 0.015 | 0.019 | 0.02 | 0.021 |
Peak value | 8856 | 9452 | 10354 | 12125 | 38455 | 66507 | 101150 |
Peak time (days) | 54 | 62 | 75 | 110 | 979 | 956 | 892 |
Vaccination rate | 0.005 | 0.01 | 0.015 | 0.02 | 0.025 |
Peak value | 23244 | 9452 | 7269 | 6370 | 5857 |
Peak time (days) | 143 | 62 | 42 | 34 | 29 |